This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

GLP1 receptor agonists and thyroid cancer risk

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer

A French nested case-control analysis (n=2,562 cases matched to 45,184 controls) found use of glucagon-like peptide 1 receptor agonists for 1-3 years was associated with an increased risk of thyroid cancer (adjusted HR 1.58, 95% CI 1.27-1.95)

Key points:

  • preclinical studies suggest that GLP-1 receptor agonists have specific effects on the thyroid gland, potentially involving the development of thyroid cancer
    • studies on this subject produced conflicting results, potentially due to a lack of statistical power.
  • results of this nationwide population-based study suggest that use of GLP-1 receptor agonists is associated with increased risk of thyroid cancer.
  • increased risk was higher in the case of 1-3 years of GLP-1 receptor agonist use
  • clinicians should be aware of this potential risk in initiating a GLP-1 receptor agonist and carefully monitor exposed patients

A systematic review and meta-analysis found GLP-1 receptor agonist treatment was associated with an increased risk of overall thyroid cancer (OR 1.52, 95%CI 1.01-2.29) (2).

Reference:

  • Bezin J et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2022; dc221148. https://doi.org/10.2337/dc22-1148
  • Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023; 1-10. doi:10.1111/dom.15382

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.